Zhong et al. reported that MEDI5117, which is a novel high-affinity anti-IL-6 antibody, completely inhibits IL-6-induced activation of STAT3 and then suppresses the tumor angiogenesis as well as the growth of several tumor types including prostate cancer [35]. Here, STAT3 is linked to prostate cancer.